Comparison of various treatments for irritable bowel syndrome
A previous therapeutic trial of factorial design showed that a combination of a psychotropic drug, a smooth-muscle relaxant, and a bulk former (lorazepam, hyoscine hydrobromide, and ispaghula husk) relieved symptoms of the irritable bowel syndrome more effectively than the same agents given singly....
Gespeichert in:
| Veröffentlicht in: | BMJ 1980-11, Vol.281 (6251), p.1317-1319 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1319 |
|---|---|
| container_issue | 6251 |
| container_start_page | 1317 |
| container_title | BMJ |
| container_volume | 281 |
| creator | Ritchie, J A Truelove, S C |
| description | A previous therapeutic trial of factorial design showed that a combination of a psychotropic drug, a smooth-muscle relaxant, and a bulk former (lorazepam, hyoscine hydrobromide, and ispaghula husk) relieved symptoms of the irritable bowel syndrome more effectively than the same agents given singly. Another trial of similar design was undertaken to compare each of these three agents with another having the equivalent clinical actions--namely, Motival (fluphenazine/nortriptylene mixture), mebeverine, and bran. Ninety-six patients took part; all received three agents, one from each of the three pairs being compared, and no placebos were used. Fifty-six patients reported a sustained symptomatic improvement, which was a significantly higher incidence than in the previous trial, when placebos were used. Ispaghula was significantly more effective than bran. The combination of ispaghula, Motival, and mebeverine improved 11 out of 12 patients--significantly more than bran, Motival, and hyoscine (five improved), or bran, lorazepam, and mebeverine (four improved). Mebeverine was significantly more effective when combined with Motival (18 out of 24 improved) than with lorazepam (10 improved). These results confirm the value of a combined therapeutic approach to the relief of the irritable bowel syndrome and suggest the possibility of synergism between agents. |
| doi_str_mv | 10.1136/bmj.281.6251.1317 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1714728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>25442080</jstor_id><sourcerecordid>25442080</sourcerecordid><originalsourceid>FETCH-LOGICAL-b585t-5ddc1d4d0503465462a3a2512f6b97c1a324ac75df78b890fbef0add9b01aefd3</originalsourceid><addsrcrecordid>eNqFkUuP0zAUhS0EGqphfgALpEhIrEjx9bsLkFAFDGI0bGC2lh3bkJLExU4H5t9zq1blsWHlWN-5x-fmEPIY6BKAqxd-3CyZgaViEpbAQd8jCxDKtNJwfp8sKKW6BSH0Q3JR6wavjGuzUuKMnOGMUJQtyMt1Hreu9DVPTU7NLX7mXW3mEt08xmmuTcql6UvpZ-eH2Pj8Iw5NvZtCyWN8RB4kN9R4cTzPyee3bz6tL9urj-_er19ftV4aObcyhA6CCFRSLhS-zBx3mJol5Ve6A8eZcJ2WIWnjzYomHxN1Iaw8BRdT4Ofk1cF3u_NjDB0GK26w29KPrtzZ7Hr7N5n6r_ZLvrWgQWhm0ODZ0aDk77tYZzv2tYvD4KaI-1otudQUOAqf_iPc5F2ZcDn00gr_OzcKVXBQdSXXWmI6RQFq9-VYLMdiOXZfjt2XgzNP_tzhNHGs4jff1DmXE0YqGDUUeXvgfZ3jzxN35ZtVmmtpr2_W9tJo80HrG3uN-ucH_T7K_-P9Ak_8se4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776136386</pqid></control><display><type>article</type><title>Comparison of various treatments for irritable bowel syndrome</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>PubMed Central</source><creator>Ritchie, J A ; Truelove, S C</creator><creatorcontrib>Ritchie, J A ; Truelove, S C</creatorcontrib><description>A previous therapeutic trial of factorial design showed that a combination of a psychotropic drug, a smooth-muscle relaxant, and a bulk former (lorazepam, hyoscine hydrobromide, and ispaghula husk) relieved symptoms of the irritable bowel syndrome more effectively than the same agents given singly. Another trial of similar design was undertaken to compare each of these three agents with another having the equivalent clinical actions--namely, Motival (fluphenazine/nortriptylene mixture), mebeverine, and bran. Ninety-six patients took part; all received three agents, one from each of the three pairs being compared, and no placebos were used. Fifty-six patients reported a sustained symptomatic improvement, which was a significantly higher incidence than in the previous trial, when placebos were used. Ispaghula was significantly more effective than bran. The combination of ispaghula, Motival, and mebeverine improved 11 out of 12 patients--significantly more than bran, Motival, and hyoscine (five improved), or bran, lorazepam, and mebeverine (four improved). Mebeverine was significantly more effective when combined with Motival (18 out of 24 improved) than with lorazepam (10 improved). These results confirm the value of a combined therapeutic approach to the relief of the irritable bowel syndrome and suggest the possibility of synergism between agents.</description><identifier>ISSN: 0007-1447</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.281.6251.1317</identifier><identifier>PMID: 6254602</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Adolescent ; Adult ; Aged ; Clinical Trials as Topic ; Colonic Diseases, Functional - therapy ; Dietary Fiber - therapeutic use ; Diverticulum ; Drug Combinations ; Drug Therapy, Combination ; Factorial design ; Female ; Fluphenazine - therapeutic use ; Humans ; Irritable bowel syndrome ; Lorazepam - therapeutic use ; Male ; Medical treatment ; Middle Aged ; Motivation ; Nortriptyline - therapeutic use ; Phenethylamines - therapeutic use ; Placebos ; Psychotropics ; Random Allocation ; Scopolamine - therapeutic use ; Smooth muscle ; Symptoms ; Writing tablets</subject><ispartof>BMJ, 1980-11, Vol.281 (6251), p.1317-1319</ispartof><rights>Copyright 1980 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Nov 15, 1980</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b585t-5ddc1d4d0503465462a3a2512f6b97c1a324ac75df78b890fbef0add9b01aefd3</citedby><cites>FETCH-LOGICAL-b585t-5ddc1d4d0503465462a3a2512f6b97c1a324ac75df78b890fbef0add9b01aefd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/25442080$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/25442080$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,803,885,27924,27925,53791,53793,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6254602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ritchie, J A</creatorcontrib><creatorcontrib>Truelove, S C</creatorcontrib><title>Comparison of various treatments for irritable bowel syndrome</title><title>BMJ</title><addtitle>Br Med J</addtitle><description>A previous therapeutic trial of factorial design showed that a combination of a psychotropic drug, a smooth-muscle relaxant, and a bulk former (lorazepam, hyoscine hydrobromide, and ispaghula husk) relieved symptoms of the irritable bowel syndrome more effectively than the same agents given singly. Another trial of similar design was undertaken to compare each of these three agents with another having the equivalent clinical actions--namely, Motival (fluphenazine/nortriptylene mixture), mebeverine, and bran. Ninety-six patients took part; all received three agents, one from each of the three pairs being compared, and no placebos were used. Fifty-six patients reported a sustained symptomatic improvement, which was a significantly higher incidence than in the previous trial, when placebos were used. Ispaghula was significantly more effective than bran. The combination of ispaghula, Motival, and mebeverine improved 11 out of 12 patients--significantly more than bran, Motival, and hyoscine (five improved), or bran, lorazepam, and mebeverine (four improved). Mebeverine was significantly more effective when combined with Motival (18 out of 24 improved) than with lorazepam (10 improved). These results confirm the value of a combined therapeutic approach to the relief of the irritable bowel syndrome and suggest the possibility of synergism between agents.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Clinical Trials as Topic</subject><subject>Colonic Diseases, Functional - therapy</subject><subject>Dietary Fiber - therapeutic use</subject><subject>Diverticulum</subject><subject>Drug Combinations</subject><subject>Drug Therapy, Combination</subject><subject>Factorial design</subject><subject>Female</subject><subject>Fluphenazine - therapeutic use</subject><subject>Humans</subject><subject>Irritable bowel syndrome</subject><subject>Lorazepam - therapeutic use</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Motivation</subject><subject>Nortriptyline - therapeutic use</subject><subject>Phenethylamines - therapeutic use</subject><subject>Placebos</subject><subject>Psychotropics</subject><subject>Random Allocation</subject><subject>Scopolamine - therapeutic use</subject><subject>Smooth muscle</subject><subject>Symptoms</subject><subject>Writing tablets</subject><issn>0007-1447</issn><issn>0959-8138</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkUuP0zAUhS0EGqphfgALpEhIrEjx9bsLkFAFDGI0bGC2lh3bkJLExU4H5t9zq1blsWHlWN-5x-fmEPIY6BKAqxd-3CyZgaViEpbAQd8jCxDKtNJwfp8sKKW6BSH0Q3JR6wavjGuzUuKMnOGMUJQtyMt1Hreu9DVPTU7NLX7mXW3mEt08xmmuTcql6UvpZ-eH2Pj8Iw5NvZtCyWN8RB4kN9R4cTzPyee3bz6tL9urj-_er19ftV4aObcyhA6CCFRSLhS-zBx3mJol5Ve6A8eZcJ2WIWnjzYomHxN1Iaw8BRdT4Ofk1cF3u_NjDB0GK26w29KPrtzZ7Hr7N5n6r_ZLvrWgQWhm0ODZ0aDk77tYZzv2tYvD4KaI-1otudQUOAqf_iPc5F2ZcDn00gr_OzcKVXBQdSXXWmI6RQFq9-VYLMdiOXZfjt2XgzNP_tzhNHGs4jff1DmXE0YqGDUUeXvgfZ3jzxN35ZtVmmtpr2_W9tJo80HrG3uN-ucH_T7K_-P9Ak_8se4</recordid><startdate>19801115</startdate><enddate>19801115</enddate><creator>Ritchie, J A</creator><creator>Truelove, S C</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19801115</creationdate><title>Comparison of various treatments for irritable bowel syndrome</title><author>Ritchie, J A ; Truelove, S C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b585t-5ddc1d4d0503465462a3a2512f6b97c1a324ac75df78b890fbef0add9b01aefd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Clinical Trials as Topic</topic><topic>Colonic Diseases, Functional - therapy</topic><topic>Dietary Fiber - therapeutic use</topic><topic>Diverticulum</topic><topic>Drug Combinations</topic><topic>Drug Therapy, Combination</topic><topic>Factorial design</topic><topic>Female</topic><topic>Fluphenazine - therapeutic use</topic><topic>Humans</topic><topic>Irritable bowel syndrome</topic><topic>Lorazepam - therapeutic use</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Motivation</topic><topic>Nortriptyline - therapeutic use</topic><topic>Phenethylamines - therapeutic use</topic><topic>Placebos</topic><topic>Psychotropics</topic><topic>Random Allocation</topic><topic>Scopolamine - therapeutic use</topic><topic>Smooth muscle</topic><topic>Symptoms</topic><topic>Writing tablets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ritchie, J A</creatorcontrib><creatorcontrib>Truelove, S C</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ritchie, J A</au><au>Truelove, S C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of various treatments for irritable bowel syndrome</atitle><jtitle>BMJ</jtitle><addtitle>Br Med J</addtitle><date>1980-11-15</date><risdate>1980</risdate><volume>281</volume><issue>6251</issue><spage>1317</spage><epage>1319</epage><pages>1317-1319</pages><issn>0007-1447</issn><issn>0959-8138</issn><eissn>1468-5833</eissn><abstract>A previous therapeutic trial of factorial design showed that a combination of a psychotropic drug, a smooth-muscle relaxant, and a bulk former (lorazepam, hyoscine hydrobromide, and ispaghula husk) relieved symptoms of the irritable bowel syndrome more effectively than the same agents given singly. Another trial of similar design was undertaken to compare each of these three agents with another having the equivalent clinical actions--namely, Motival (fluphenazine/nortriptylene mixture), mebeverine, and bran. Ninety-six patients took part; all received three agents, one from each of the three pairs being compared, and no placebos were used. Fifty-six patients reported a sustained symptomatic improvement, which was a significantly higher incidence than in the previous trial, when placebos were used. Ispaghula was significantly more effective than bran. The combination of ispaghula, Motival, and mebeverine improved 11 out of 12 patients--significantly more than bran, Motival, and hyoscine (five improved), or bran, lorazepam, and mebeverine (four improved). Mebeverine was significantly more effective when combined with Motival (18 out of 24 improved) than with lorazepam (10 improved). These results confirm the value of a combined therapeutic approach to the relief of the irritable bowel syndrome and suggest the possibility of synergism between agents.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>6254602</pmid><doi>10.1136/bmj.281.6251.1317</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1447 |
| ispartof | BMJ, 1980-11, Vol.281 (6251), p.1317-1319 |
| issn | 0007-1447 0959-8138 1468-5833 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1714728 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing; PubMed Central |
| subjects | Adolescent Adult Aged Clinical Trials as Topic Colonic Diseases, Functional - therapy Dietary Fiber - therapeutic use Diverticulum Drug Combinations Drug Therapy, Combination Factorial design Female Fluphenazine - therapeutic use Humans Irritable bowel syndrome Lorazepam - therapeutic use Male Medical treatment Middle Aged Motivation Nortriptyline - therapeutic use Phenethylamines - therapeutic use Placebos Psychotropics Random Allocation Scopolamine - therapeutic use Smooth muscle Symptoms Writing tablets |
| title | Comparison of various treatments for irritable bowel syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A05%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20various%20treatments%20for%20irritable%20bowel%20syndrome&rft.jtitle=BMJ&rft.au=Ritchie,%20J%20A&rft.date=1980-11-15&rft.volume=281&rft.issue=6251&rft.spage=1317&rft.epage=1319&rft.pages=1317-1319&rft.issn=0007-1447&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.281.6251.1317&rft_dat=%3Cjstor_pubme%3E25442080%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776136386&rft_id=info:pmid/6254602&rft_jstor_id=25442080&rfr_iscdi=true |